Open AccessLack of Response to Imatinib in Melanoma Carrying Rare <b><i>KIT</i></b> Mutation р.T632I
Author(s) -
Kristina V. Orlova,
Grigoriy A. Yanus,
Svetla. Aleksakhina,
Aigul R. Venina,
Aglaya G. Iyevleva,
Лев В. Демидов,
Evgeny N. Imyanitov
Publication year - 2019
Publication title -
case reports in oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.365
H-Index - 19
ISSN - 1662-6575
DOI - 10.1159/000495782
Subject(s) - imatinib , medicine , melanoma , cancer research , mutation , imatinib mesylate , genetics , biology , gene , myeloid leukemia
Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with KIT р.T632I mutation, who failed to respond to imatinib.